Abstract: Journal of Clinical Medicine Article Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy Marco Cosentino 1, *,† , Veronica Vernocchi 2, *,† , Stefano Martini 1 , Franca Marino 1 , Barbara Allasino 2 , Maria Antonietta Bàlzola 2 , Fabio Burigana 2 , Alberto Dallari 2 , Carlo Servo Florio Pagano 2 , Antonio Palma 2 , Mauro Rango 2 and on behalf of IppocrateOrg Association Working Group for the Early Outpatient Treatment of COVID-19 ‡ 1 2 * † ‡ Citation: Cosentino, M.; Vernocchi, V.; Martini, S.; Marino, F.; Allasino, B.; Bàlzola, M.A.; Burigana, F.; Dallari, A.; Pagano, C.S.F.; Palma, A.; et al. Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy. J. Clin. Med. 2022, 11, 6138. https://doi.org/ 10.3390/jcm11206138 Academic Editor: Jose-Manuel Ramos-Rincon Received: 13 September 2022 Accepted: 16 October 2022 Center for Research in Medical Pharmacology, University of Insubria, 21100 Varese, Italy IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland Correspondence: marco.cosentino@uninsubria.it (M.C.); info@ippocrateorg.org (V.V.) These authors contributed equally to this work. Collaborators/Membership of the Group/Team Name is provided in the Appendix A. Abstract: COVID-19 was declared a pandemic in March 2020. The knowledge of COVID-19 pathophysiology soon provided a strong rationale for the early use of both anti-inflammatory and antithrombotic drugs; however, its evidence was slowly and partially incorporated into institutional guidelines. The unmet needs of COVID-19 outpatients were taken care of by networks of physicians and researchers. We analyse the characteristics, management and outcomes in COVID-19 outpatients who were taken care of by physicians within the IppocrateOrg Association. In this observational retrospective study, volunteering doctors provided data on 392 COVID-19 patients. The mean age of patients was 48.5 years (range: 0.5–97), and patients were taken care of in COVID-19 stage 0 (15.6%), stage 1 (50.0%), stage 2a (28.8%) and stage 2b (5.6%). Many patients were overweight (26%) or obese (11.5%), with chronic comorbidities (34.9%), mainly cardiovascular (23%) and metabolic (13.3%). The most frequently prescribed drugs included: vitamins and supplements (98.7%), aspirin (66.1%), antibiotics (62%), glucocorticoids (41.8%), hydroxychloroquine (29.6%), enoxaparin (28.6%), colchicine (8.9%), oxygen therapy (6.9%), and ivermectin (2.8%). Hospitalization occurred in 5.8% of cases, mainly in stage 2b (27.3%). A total of 390 patients (99.6%) recovered; one patient was lost at follow up, and one patient died after hospitalization. This is the first real-world study describing the behaviours of physicians caring for COVID-19 outpatients, and the outcomes of COVID-19 early treatment. The lethality in this cohort was 0.2%, while overall, and over the same period, the COVID-19 lethality in Italy was over 3%. The drug use described in this study appears effective and safe. The present evidence should be carefully considered by physicians and political decision makers. Keywords: SARS-CoV-2; COVID-19; primary care; family medicine; early outpatient treatment Published: 18 October 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in